Initial testing of lenalidomide by the pediatric preclinical testing program.

ABSTRACT:

Background

Lenalidomide, a novel immunomodulatory agent, is reported to modulate stem cell differentiation, and have direct antiproliferative activity as well as inhibit inflammation and hyperalgesia. On the basis of this varied pharmacological profile, lenalidomide is under investigation as a treatment for a range of oncologic indications.

Procedures

Lenalidomide was evaluated against the PPTP in vitro panel using 96-hr exposure at concentrations ranging from 1 nM to 10 µM. It was tested against the PPTP in vivo panels at a dose of 30 mg/kg administered orally (PO) once daily for a planned for 6 weeks.

Results

In vitro activity was not observed at concentrations up to 10 µM. Lenalidomide was well tolerated, and induced significant differences in EFS distribution comp

SUBMITTER: Reynolds CP 

PROVIDER: S-EPMC4505747 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature